Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

• Status: Completed
• Trial end date: 2011-10-10
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study was to evaluate efficacy of prophylactic Ingavirin intake by people having contact with sick people infected with influenza and other acute respiratory viral infections

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Valenta Pharm JSC
• Treatments: Pentanedioic acid imidazolyl ethanamide

Criteria

Inclusion Criteria:

• Participants who do have continuous contact with ill person (staff members, dormitory, family members), laboratory confirmed viral origin, during influenza/other acute viral respiratory disease season

• First exposure with the ill person who is present with symptoms of flu or acute respiratory viral infection (fever, intoxication, catarrhal symptoms) ≤ 48 hours

• Signed Informed Contest to participate in the study

• Contraception throughout the study

Exclusion Criteria:

• Interferone or interferone inducers intake, or substances with action on immune system intake less then 3 months before inclusion

• Anti-virals intake, other then investigational drug, throughout the study

• Vaccination for Influenza less than 1 year before inclusion

• Pregnant or lactating